TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68

Benzinga Newsdesk www.benzinga.com Positive 74.3%

Neg 0% Neu 0% Pos 74.3%

TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.